The United States Eliquis Market size is reached a valuation of USD xx.x Billion in 2023, with projections to achieve USD xx.x Billion by 2031, demonstrating a compound annual growth rate (CAGR) of xx.x% from 2024 to 2031.
United States Eliquis Market By Application
- Stroke Prevention in Atrial Fibrillation (SPAF)
- Deep Vein Thrombosis (DVT) Treatment
- Pulmonary Embolism (PE) Treatment
- Prophylaxis of Deep Vein Thrombosis (DVT)
- Other Cardiovascular Applications
Eliquis (apixaban) is a widely prescribed anticoagulant in the United States, primarily used across several key applications:
The largest segment of the Eliquis market is in Stroke Prevention in Atrial Fibrillation (SPAF), where it is favored for its efficacy in reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Additionally, Eliquis plays a significant role in the treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), offering effective and safe therapeutic options. Another critical application is in the prophylaxis of DVT, particularly in patients undergoing hip or knee replacement surgery. Beyond these primary uses, Eliquis finds application in other cardiovascular conditions, contributing to its broad market reach in the anticoagulant sector.